Alexy Manikhas

Learn More
BACKGROUND This randomized phase II trial was designed to compare the rate of pathologic complete response (pCR) induced by neoadjuvant cyclophosphamide plus doxorubicin (AC) followed by ixabepilone or paclitaxel in women with early stage breast cancer (BC). Expression of βIII-tubulin as a predictive marker was also evaluated. PATIENTS AND METHODS Women(More)
TPS108 Background: The EGFR pathways are important therapeutic targets in HER2/neu+ BC. Lapatinib (L) a dual, inhibitor of EGFR and HER2/neu tyrosine kinase activity improves overall survival (OS) in patients with metastatic BC when added to paclitaxel (SABCS 2010:P3-1424).The relative efficacy of L + taxane compared to trastuzumab (T) + taxane in the(More)
  • 1